451 related articles for article (PubMed ID: 37653265)
21. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
22. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
[TBL] [Abstract][Full Text] [Related]
23. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
24. Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade.
Zheng C; Xiao Y; Chen C; Zhu J; Yang R; Yan J; Huang R; Xiao W; Wang Y; Huang C
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33876189
[TBL] [Abstract][Full Text] [Related]
25. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8
Huang MY; Chen YC; Lyu WY; He XY; Ye ZH; Huang CY; He XL; Chen X; Chen X; Zhang B; Kai G; Zhang X; Li T; Huang M; Lu JJ
Pharmacol Res; 2023 Dec; 198():106988. PubMed ID: 37984507
[TBL] [Abstract][Full Text] [Related]
26. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
27. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
28. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
29. Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells.
Zhang H; Zhang P; Lin X; Tan L; Wang Y; Jia X; Wang K; Li X; Sun D
Front Immunol; 2024; 15():1366096. PubMed ID: 38596689
[TBL] [Abstract][Full Text] [Related]
30. IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model.
Feng Y; Yan S; Lam SK; Ko FCF; Chen C; Khan M; Ho JC
Lung Cancer; 2022 Dec; 174():14-26. PubMed ID: 36272280
[TBL] [Abstract][Full Text] [Related]
31. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S
Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468
[TBL] [Abstract][Full Text] [Related]
32. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
33. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Hijazi A; Antoniotti C; Cremolini C; Galon J
Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
[TBL] [Abstract][Full Text] [Related]
34. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
[TBL] [Abstract][Full Text] [Related]
35. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
36. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
Meng Y; Liu H; Zhu H; Zhang W; Sun D; Han X; Liu Y; Luo G
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212125
[TBL] [Abstract][Full Text] [Related]
37. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
[TBL] [Abstract][Full Text] [Related]
38. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
39. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
40. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]